SAN DIEGO, September 22, 2021 – ProSciento, Inc., a specialty clinical research organization (CRO) focused exclusively on diabetes, obesity, non-alcoholic steatohepatitis (NASH), and related metabolic diseases, announced the appointment of Michelle Thompson, PhD, MBA, as Executive Vice President of Global Business Development.
“We are delighted to welcome Michelle to our leadership team. Her extensive experience in strategic partnerships and business development within the clinical research industry is a key asset as we continue to expand our metabolic disease-focused specialty CRO services globally, including unique and highly differentiating patient engagement programs. She brings values-driven leadership and scientific acumen to our already strong and growing team of distinguished business development professionals,” commented Dr. Marcus Hompesch, ProSciento’s Chairman and Chief Executive Officer.
“It’s an honor to join ProSciento, a growing and innovative company focused on improving the lives of patients affected by metabolic diseases. ProSciento is truly a stand-out in the clinical research industry through its cutting-edge science, novel patient access blueprint, and a dedication to whole-person care within important chronic diseases. I am energized and proud to be a part of this organization and look forward to leading the business development team,” said Dr. Thompson.
Dr. Thompson’s career in business development and alliance management spans more than 25 years within several sectors of life sciences, including senior management roles at PPD, Covance, Focus Bio-Inova, Nextrials, and Tria Healthcare. Within that span she was also at PRA Health Sciences for seven years, which included the role of Vice President of Business Development. Dr. Thompson also spent a portion of her career in academia, as an assistant professor of marketing at Rockhurst University in Kansas City and an adjunct professor of psychology at the University of Connecticut. She received her PhD in Neuroscience/Psychology from the University of Connecticut and her MBA from the University of North Carolina.
About ProSciento, Inc.
ProSciento is the leading specialized clinical research organization (CRO) focused on NASH, diabetes, obesity, and related metabolic diseases. ProSciento works with biopharma companies worldwide to support their outsourced clinical research needs with comprehensive and customized services for multinational, early development clinical trial programs. Founded in 2003, ProSciento has conducted more than 325 clinical studies for diabetes, NASH, and obesity, and has contributed to the development of numerous approved metabolic drugs and devices on the global marketplace. For more information, please visit www.prosciento.com.
For business development inquiries, please contact:
For media inquiries, please contact:
Senior Director, Corporate Communications, ProSciento, Inc.
For clinical trial enrollment inquires, please contact:
Tel: +1 (866) 308-7427